T2DM
Conditions
Interventions
case series:None
Sponsors
The Third Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 20 to 60 years (including 20 and 60 years old) when signing the Informed Consent (ICD). 2. The body mass index (BMI) is 27.5 kg/m^2 to 32.5 kg/m^2. 3. T2DM is diagnosed according to WHO standards for at least 6 months; WHO diagnostic criteria: (1) Typical symptoms of diabetes (polydipsia and polydipsia, polyuria, polyphagia, unexplained weight loss) plus random blood glucose >= 11.1 (mmol/L); (2) Fasting blood glucose >=7.0 (mmol/L); (3) 2 h after glucose load, blood glucose >= 11.1 (mmol/L) and no typical diabetic symptoms should be rechecked and confirmed another day. Note: Fasting state refers to no calories eaten for at least 8 hours; random blood glucose refers to blood glucose at any time of the day regardless of the last meal time, and cannot be used to diagnose abnormal fasting blood glucose or impaired glucose tolerance. 4. C peptide> 1.0 ng/mL (0.3 nmol/L). 5. Willing and able to comply with the research process stipulated in the program. 6. Able to understand and sign the research informed consent form. If he is illiterate, he is willing to put his fingerprints on the informed consent form.
Exclusion criteria
Exclusion criteria: 1. The medical history of T2DM lasts for more than 15 years; 2. A history of drug and/or alcohol abuse within 2 years prior to the screening visit; 3. Any previous major gastrointestinal surgery (such as any gastrointestinal surgery for resection, etc.) . Allowed history of gastrointestinal surgery includes: appendectomy, cholecystectomy, liver biopsy and endoscopic surgery; 4. During the period from before the operation to the end of the operation, a combined operation is planned (except for endoscopy); 5. Women of childbearing age who are pregnant or breastfeeding during screening and surgery, or plan to become pregnant during follow-up; 6. Mental diseases that may affect compliance with clinical research, including dementia, active psychosis, severe depression, or attempted suicide; 7. Patients with severe kidney disease, uncontrolled hypertension (>=150/100mmHg), symptomatic ischemic heart disease, cerebral infarction or arteriosclerosis obliterans, malignant tumors, and other serious underlying diseases; 8. Patients who meet any of the following conditions: (1) Inflammatory diseases of the intestinal tract, including severe refractory esophagitis, gastric ulcer, duodenal ulcer, or specific inflammation that has been active in the past 10 years, such as Crohns disease or ulcerative colitis; (2) Glutamate decarboxylase antibody (GADA) and protein tyrosine phosphatase antibody (IA-2A) were tested positive; (3) Immune function is low, such as caused by long-term oral steroid hormones, cancer chemotherapy drugs, or immunodeficiency diseases; 9. Participate in any other clinical research (except for registration or investigational research) within 30 days before surgery or 5 half-lives of the trial drug (which may be longer), or during the research process; 10. Researchers consider patients who are not suitable for participating in this study based on risk and benefit considerations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| insulin clamp;glycosylated hemoglobin;oral glucose tolerance test;liver function;blood glucose; | — |
Secondary
| Measure | Time frame |
|---|---|
| body mass index;blood pressure;waist hip rate;serum lipid;blood routine examination;sex hormone; | — |
Countries
China
Contacts
Public ContactZhu Liyong
The Third Xiangya Hospital of Central South University
Outcome results
None listed